Listed

Tonix Pharmaceuticals Holding Corp.

TNXPNasdaqCIK 1430306HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$13.5mRevenue, Q2 FY2026, three months to 2026-06-30$13.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 10, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$13.5mRevenue, Q2 FY2026, three months to 2026-06-30$13.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Report this figure+577.9% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−314.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$42.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Revenue: $13.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Report this figure+1102.2 pts on a year earlier
  • Net margin−299.4%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$40.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Revenue: $13.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Report this figure+1115.6 pts on a year earlier
  • Diluted EPS−$2.44Diluted EPS, Q2 FY2026, three months to 2026-06-30−$2.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Report this figure+36.8% on a year earlier
  • Free cash flow−$42.8mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$42.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001999371-26-017452. Derived: 6-month figure less the 3-month figure.Capital expenditure: $587.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001999371-26-017452. Derived: 6-month figure less the 3-month figure.Report this figure−178.8% on a year earlier

Last eight quarters

Full statements
Revenue$13.5mOperating margin −314.1%
Diluted EPS−$2.44, Q2 FY2026
Free cash flow−$42.8m, Q2 FY2026
Tonix Pharmaceuticals Holding Corp., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m2.8Revenue, Q3 FY2024, three months to 2024-09-30$2.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001999371-25-017370.Report this figure2.6Revenue, Q4 FY2024, three months to 2024-12-31$2.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001999371-26-005730. Derived: 12-month figure less the 9-month figure.Report this figure2.4Revenue, Q1 FY2025, three months to 2025-03-31$2.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001999371-26-010486.Report this figure2.0Revenue, Q2 FY2025, three months to 2025-06-30$2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Report this figure3.3Revenue, Q3 FY2025, three months to 2025-09-30$3.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001999371-25-017370.Report this figure5.4Revenue, Q4 FY2025, three months to 2025-12-31$5.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001999371-26-005730. Derived: 12-month figure less the 9-month figure.Report this figure6.9Revenue, Q1 FY2026, three months to 2026-03-31$6.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001999371-26-010486.Report this figure13.5Revenue, Q2 FY2026, three months to 2026-06-30$13.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(551.2%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$15.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001999371-25-017370.Revenue: $2.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001999371-25-017370.Report this figure(870.6%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$22.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001999371-26-005730. Derived: 12-month figure less the 9-month figure.Revenue: $2.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001999371-26-005730. Derived: 12-month figure less the 9-month figure.Report this figure(660.9%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$16.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001999371-26-010486.Revenue: $2.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001999371-26-010486.Report this figure(1416.2%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$28.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Revenue: $2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Report this figure(1005.1%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$33.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001999371-25-017370.Revenue: $3.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001999371-25-017370.Report this figure(895.8%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$48.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001999371-26-005730. Derived: 12-month figure less the 9-month figure.Revenue: $5.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001999371-26-005730. Derived: 12-month figure less the 9-month figure.Report this figure(603.9%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$41.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001999371-26-010486.Revenue: $6.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001999371-26-010486.Report this figure(314.1%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$42.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Revenue: $13.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Report this figure
Net margin%(503.6%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$14.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001999371-25-017370.Revenue: $2.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001999371-25-017370.Report this figure(856.2%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$22.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001999371-26-005730. Derived: 12-month figure less the 9-month figure.Revenue: $2.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001999371-26-005730. Derived: 12-month figure less the 9-month figure.Report this figure(692.8%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$16.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Revenue: $2.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001999371-26-010486.Report this figure(1415.0%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$28.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Revenue: $2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Report this figure(972.9%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$32.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001999371-25-017370.Revenue: $3.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001999371-25-017370.Report this figure(870.3%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$46.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001999371-26-005730. Derived: 12-month figure less the 9-month figure.Revenue: $5.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001999371-26-005730. Derived: 12-month figure less the 9-month figure.Report this figure(584.4%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$40.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Revenue: $6.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001999371-26-010486.Report this figure(299.4%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$40.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Revenue: $13.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Report this figure
Diluted EPS$ per share(22.68)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$22.68 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001999371-25-017370.Report this figurenot reported (Diluted EPS not reported)(2.84)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$2.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001999371-26-010486.Report this figure(3.86)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$3.86 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Report this figure(3.59)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$3.59 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001999371-25-017370.Report this figurenot reported (Diluted EPS not reported)(2.93)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$2.93 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001999371-26-010486.Report this figure(2.44)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$2.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001999371-26-017452.Report this figure
Free cash flow$m(18.8)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$18.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001999371-25-017370. Derived: 9-month figure less the 6-month figure.Capital expenditure: $9.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001999371-25-017370. Derived: 9-month figure less the 6-month figure.Report this figure(14.6)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$14.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001999371-26-005730. Derived: 12-month figure less the 9-month figure.Capital expenditure: $3.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001999371-26-005730. Derived: 12-month figure less the 9-month figure.Report this figure(16.6)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$16.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001999371-26-010486.Capital expenditure: $6.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001999371-26-010486.Report this figure(15.4)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$14.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001999371-26-017452. Derived: 6-month figure less the 3-month figure.Capital expenditure: $527.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001999371-26-017452. Derived: 6-month figure less the 3-month figure.Report this figure(29.7)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$28.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001999371-25-017370. Derived: 9-month figure less the 6-month figure.Capital expenditure: $962.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001999371-25-017370. Derived: 9-month figure less the 6-month figure.Report this figure(41.5)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$39.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001999371-26-005730. Derived: 12-month figure less the 9-month figure.Capital expenditure: $1.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001999371-26-005730. Derived: 12-month figure less the 9-month figure.Report this figure(44.0)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$42.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001999371-26-010486.Capital expenditure: $1.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001999371-26-010486.Report this figure(42.8)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$42.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001999371-26-017452. Derived: 6-month figure less the 3-month figure.Capital expenditure: $587.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001999371-26-017452. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$13.1mOperating margin −959.1%
Diluted EPS−$14.57, FY2025
Free cash flow−$103.2m, FY2025
Tonix Pharmaceuticals Holding Corp., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$mnot reported (Revenue not reported)not reported (Revenue not reported)7.8Revenue, FY2023, twelve months to 2023-12-31$7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-18, accession 0001999371-25-002786.Report this figure10.1Revenue, FY2024, twelve months to 2024-12-31$10.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001999371-26-005730.Report this figure13.1Revenue, FY2025, twelve months to 2025-12-31$13.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001999371-26-005730.Report this figure
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)(1523.9%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$118.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-18, accession 0001999371-25-002786.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-18, accession 0001999371-25-002786.Report this figure(1354.3%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$136.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001999371-26-005730.Revenue: $10.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001999371-26-005730.Report this figure(959.1%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$125.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001999371-26-005730.Revenue: $13.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001999371-26-005730.Report this figure
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)(1501.8%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$116.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-18, accession 0001999371-25-002786.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-18, accession 0001999371-25-002786.Report this figure(1288.3%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$130.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001999371-26-005730.Revenue: $10.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001999371-26-005730.Report this figure(946.2%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$124.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001999371-26-005730.Revenue: $13.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001999371-26-005730.Report this figure
Diluted EPS$ per share(8.10)Diluted EPS, FY2021, twelve months to 2021-12-31−$8.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-13, accession 0001387131-23-003377.Report this figure(20.01)Diluted EPS, FY2022, twelve months to 2022-12-31−$20.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-04-01, accession 0001999371-24-004297.Report this figure(14720.25)Diluted EPS, FY2023, twelve months to 2023-12-31−$14720.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-18, accession 0001999371-25-002786.Report this figure(176.60)Diluted EPS, FY2024, twelve months to 2024-12-31−$176.60 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-12, accession 0001999371-26-005730.Report this figure(14.57)Diluted EPS, FY2025, twelve months to 2025-12-31−$14.57 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-12, accession 0001999371-26-005730.Report this figure
Free cash flow$m(111)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$75.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-13, accession 0001387131-23-003377.Capital expenditure: $35.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-13, accession 0001387131-23-003377.Report this figure(146)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$98.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-04-01, accession 0001999371-24-004297.Capital expenditure: $48.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-04-01, accession 0001999371-24-004297.Report this figure(110)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$102.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-18, accession 0001999371-25-002786.Capital expenditure: $7.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-18, accession 0001999371-25-002786.Report this figure(61.0)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$60.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001999371-26-005730.Capital expenditure: $120.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001999371-26-005730.Report this figure(103)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$99.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001999371-26-005730.Capital expenditure: $3.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001999371-26-005730.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Tonix Pharmaceuticals Holding Corp.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$17.8m1,398,041Added+429,864
Point72 Asset Management, L.P.2026-06-30$14.9m1,166,752Added+1,041,338
MILLENNIUM MANAGEMENT LLC2026-06-30$12.3m966,932Added+747,259
AQR CAPITAL MANAGEMENT LLC2026-06-30$11.3m882,595Added+721,387
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$8.8m691,895Added+173,245
Jones Hill Capital LP2026-06-30$8.0m625,428Added+173,312
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$5.0m395,260Added+81,969
Ishara Investments LP2026-06-30$4.3m338,250New+338,250
STATE STREET CORP2026-06-30$3.5m271,374Added+40,767
UBS Group AG2026-06-30$3.0m231,682Added+4

Recent filings

All 1,508 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Tonix Pharmaceuticals Holding Corp., recent filings
FiledFormWhat it isAccession number
2026-10-1511:00 ET8-K2.02 Results of operations; 8.01 Other events0001493152-26-047139
2026-10-0221:20 ET8-K8.01 Other events0001493152-26-045603
2026-09-2211:05 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001493152-26-043644
2026-09-0811:05 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001493152-26-041689
2026-08-1820:00 ET8-K5.02 Departure or appointment of officers or directors; 8.01 Other events0001493152-26-039000
2026-08-1012:09 ET10-QQuarterly reportPeriod 2026-06-300001999371-26-017452
2026-08-1011:15 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001493152-26-036740
2026-08-0311:05 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001493152-26-035741
2026-07-2120:05 ET8-K5.02 Departure or appointment of officers or directors0001493152-26-034079
2026-07-1311:05 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001493152-26-032925

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 12, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1430306
Tickers
TNXP
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
NV
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
TAMANDARE EXPLORATIONS INC. (to 2011-10-17)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. Listed shows no prices and gives no investment advice.